Literature DB >> 33871897

Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections.

Ruwen Böhm1, Claudia Bulin1, Vicki Waetzig1, Ingolf Cascorbi1, Hans-Joachim Klein2, Thomas Herdegen1.   

Abstract

Entities:  

Keywords:  COVID-19; coronavirus; drug repositioning; drug repurposing; influenza; pharmacovigilance

Year:  2021        PMID： 33871897     DOI： 10.1111/bcp.14868

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  4 in total

1.  Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions.

Authors:  Long Meng; Jing Huang; Feng Qiu; Xuefeng Shan; Lin Chen; Shusen Sun; Yuwei Wang; Junqing Yang
Journal:  Front Pharmacol       Date:  2022-03-14       Impact factor: 5.810

Review 2.  Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports.

Authors:  Theodoros G Soldatos; Sarah Kim; Stephan Schmidt; Lawrence J Lesko; David B Jackson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-02-20

3.  Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study.

Authors:  Kevin Pozsgai; Gergő Szűcs; Anikó Kőnig-Péter; Orsolya Balázs; Péter Vajda; Lajos Botz; Róbert György Vida
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

4.  Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data.

Authors:  Quanfeng Zhao; Pan Ma; Peishu Fu; Jiayu Wang; Kejing Wang; Lin Chen; Yang Yang
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.